A systems-oriented Ayurvedic approach in chronic plaque psoriasis with renal inflammatory indicators: a 2-year longitudinal case report

• by Sreelekshmi Mallika, Arathy Menon, Vishnu Unnikrishnan, Preethi Mohan

• July 6, 2026

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

• by Zitong Wang, Jingyu Zhang, Suwen Liu, Hongxiang Chen

• June 24, 2026

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

• by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

• July 2, 2026

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

• by Kathryn Wighton

• May 29, 2026

• 2 min